Biotech · Private company · Boxborough, MA, US
HelixBind, Inc.
Track this companyFree. Adds HelixBind, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials10 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- RaPID/BSI TestBacteremiaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole BloodUNKNOWN · started Oct 1, 2019ClinicalTrials.gov NCT04147975 · fetched Nov 12, 2026
NIH awards10
- Automated system for the direct from blood characterization of bloodstream infectionsFiscal year 2026 · $1MNIH RePORTER 1R44AI197309-01 · fetched Nov 12, 2026
- Direct-from-specimen characterization of bloodstream infectionsFiscal year 2026 · $1MNIH RePORTER 2R44AI157322-04A1 · fetched Nov 12, 2026
- Direct-from-specimen identification of pathogens common in endocarditisFiscal year 2026 · $986.9KNIH RePORTER 5R44AI136064-07 · fetched Nov 12, 2026
- An automated culture-free system for the identification of bloodstream infections direct from bloodFiscal year 2026 · $1MNIH RePORTER 5R44AI186712-03 · fetched Nov 12, 2026
- Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.Fiscal year 2026 · $1MNIH RePORTER 5SB1AI183963-03 · fetched Nov 12, 2026
- Direct-from-specimen identification of pathogens common in endocarditisFiscal year 2025 · $1MNIH RePORTER 5R44AI136064-06 · fetched Nov 12, 2026
- Diagnostic tool for assessment and tracking of microbial load in bloodstream infectionsFiscal year 2025 · $996.5KNIH RePORTER 5R44AI174578-03 · fetched Nov 12, 2026
- An automated culture-free system for the identification of bloodstream infections direct from bloodFiscal year 2025 · $1MNIH RePORTER 5R44AI186712-02 · fetched Nov 12, 2026
- Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditisFiscal year 2025 · $1MNIH RePORTER 5SB1AI172440-03 · fetched Nov 12, 2026
- Commercialization Readiness Pilot (CRP) program support for: Ultra-sensitive, direct-from-blood, molecular detection of Borrelia infections.Fiscal year 2025 · $1MNIH RePORTER 5SB1AI183963-02 · fetched Nov 12, 2026